BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

Even with a COVID-19-related lull in the first half of 2020, investors’ appetite for new biotech listings on NASDAQ far surpassed demand in recent years, leading to a record-setting year for IPOs. According...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...
BioCentury | Nov 11, 2020
Management Tracks

Novavax brings in Tesaro’s Covino as it readies to market two vaccines; plus moves at Werewolf, Editas, Magenta, Pharming, Marinus and more

Novavax Inc. (NASDAQ:NVAX) hired Gregory Covino as EVP and CFO as the company prepares to commercialize COVID-19 vaccine candidate NVXCoV2373 and flu vaccine NanoFlu. Covino succeeds EVP John Trizzino, who will become chief commercial officer while...
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

...mass production of Sputnik V, which is slated to begin in September, by portfolio companies R-Pharm CJSC...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

...risk in parallel with clinical development. The company’s latest manufacturing deal, an agreement with Russia’s R-Pharm CJSC...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

...a veteran of UCB S.A. (Euronext:UCB) who was head of global biotech process development at R-Pharm CJSC...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

...to Zentalis, Epperly served as CFO for PsiOxus Therapeutics Ltd. and the U.S. subsidiary of R-Pharm CJSC...
BioCentury | Nov 13, 2019
Finance

Conjugate company Avidity preps for first dystrophy study with $100M series C

Avidity’s $100 million series C round will allow it to evaluate clinical proof of concept for the first antibody-oligonucleotide conjugate from its platform. The company believes it can also fund early clinical development of a...
Items per page:
1 - 10 of 826
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...
BioCentury | Dec 23, 2020
Finance

NASDAQ IPOs’ class of 2020 far outpaces prior years: Data Byte

Even with a COVID-19-related lull in the first half of 2020, investors’ appetite for new biotech listings on NASDAQ far surpassed demand in recent years, leading to a record-setting year for IPOs. According...
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

As 2020’s record-setting run of biotech IPOs nears its end, Canadian mAb developer AbCellera rode enthusiasm for its COVID-19 treatment to one of the year’s biggest offerings, then nearly tripled its value in the early...
BioCentury | Nov 11, 2020
Management Tracks

Novavax brings in Tesaro’s Covino as it readies to market two vaccines; plus moves at Werewolf, Editas, Magenta, Pharming, Marinus and more

Novavax Inc. (NASDAQ:NVAX) hired Gregory Covino as EVP and CFO as the company prepares to commercialize COVID-19 vaccine candidate NVXCoV2373 and flu vaccine NanoFlu. Covino succeeds EVP John Trizzino, who will become chief commercial officer while...
BioCentury | Aug 12, 2020
Regulation

After speedy approval on immunogenicity data, Russia readies Phase III study of COVID-19 vaccine ‘Sputnik’

...mass production of Sputnik V, which is slated to begin in September, by portfolio companies R-Pharm CJSC...
BioCentury | Jul 21, 2020
Product Development

Two-dose schedule, infection levels may shift timelines for AZ-Oxford vaccine

...risk in parallel with clinical development. The company’s latest manufacturing deal, an agreement with Russia’s R-Pharm CJSC...
BioCentury | Mar 12, 2020
Management Tracks

Hoerr takes helm from Menichella at CureVac; plus Genmab hires Mancini as COO, Tricida, Akcea, Refuge, Adaptate, Thermo Fisher and more

German mRNA company CureVac AG said founder and Chairman Ingmar Hoerr is replacing Daniel Menichella as CEO. Menichella joined the company as CBO as well as CEO of CureVac’s U.S. subsidiary in January 2017, becoming...
BioCentury | Jan 7, 2020
Finance

VectivBio reunites ex-Therachon management, VCs for short bowel program

...a veteran of UCB S.A. (Euronext:UCB) who was head of global biotech process development at R-Pharm CJSC...
BioCentury | Dec 17, 2019
Company News

Management Tracks: Dynavax, Merus name CEOs; plus Grail hires a commercial lead, Seres, Zentalis, Nimbus and more

...to Zentalis, Epperly served as CFO for PsiOxus Therapeutics Ltd. and the U.S. subsidiary of R-Pharm CJSC...
BioCentury | Nov 13, 2019
Finance

Conjugate company Avidity preps for first dystrophy study with $100M series C

Avidity’s $100 million series C round will allow it to evaluate clinical proof of concept for the first antibody-oligonucleotide conjugate from its platform. The company believes it can also fund early clinical development of a...
Items per page:
1 - 10 of 826